CN108883156A - 用干扰素λ治疗丁型肝炎病毒感染 - Google Patents

用干扰素λ治疗丁型肝炎病毒感染 Download PDF

Info

Publication number
CN108883156A
CN108883156A CN201780020097.4A CN201780020097A CN108883156A CN 108883156 A CN108883156 A CN 108883156A CN 201780020097 A CN201780020097 A CN 201780020097A CN 108883156 A CN108883156 A CN 108883156A
Authority
CN
China
Prior art keywords
hdv
patient
interferon lambda
treatment
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780020097.4A
Other languages
English (en)
Chinese (zh)
Inventor
爱德华多·布鲁诺·马丁斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aigerfeng Innovative Therapy Co
Original Assignee
Egger Horn Biological Pharmacy Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egger Horn Biological Pharmacy Co Ltd filed Critical Egger Horn Biological Pharmacy Co Ltd
Publication of CN108883156A publication Critical patent/CN108883156A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201780020097.4A 2016-02-19 2017-02-17 用干扰素λ治疗丁型肝炎病毒感染 Pending CN108883156A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662297759P 2016-02-19 2016-02-19
US62/297,759 2016-02-19
PCT/US2017/018466 WO2017143253A1 (en) 2016-02-19 2017-02-17 Treatment of hepatitis delta virus infection with interferon lambda

Publications (1)

Publication Number Publication Date
CN108883156A true CN108883156A (zh) 2018-11-23

Family

ID=59625481

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780020097.4A Pending CN108883156A (zh) 2016-02-19 2017-02-17 用干扰素λ治疗丁型肝炎病毒感染

Country Status (17)

Country Link
US (2) US10953072B2 (https=)
EP (2) EP3416675B9 (https=)
JP (3) JP7674628B2 (https=)
KR (1) KR20180110127A (https=)
CN (1) CN108883156A (https=)
CY (1) CY1124220T1 (https=)
DK (1) DK3416675T3 (https=)
ES (2) ES2874592T3 (https=)
HR (1) HRP20210862T1 (https=)
HU (1) HUE055343T2 (https=)
LT (1) LT3416675T (https=)
PL (1) PL3416675T3 (https=)
PT (1) PT3416675T (https=)
RS (1) RS61944B1 (https=)
SI (1) SI3416675T1 (https=)
SM (1) SMT202100335T1 (https=)
WO (1) WO2017143253A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114555079A (zh) * 2019-10-16 2022-05-27 艾格尔峰生物制药有限公司 治疗丁型肝炎病毒感染的方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016172342A1 (en) 2015-04-21 2016-10-27 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
JP7674628B2 (ja) 2016-02-19 2025-05-12 イーアイティー・ファーマ・インコーポレイテッド インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置
GB201621728D0 (en) 2016-12-20 2017-02-01 Ucb Biopharma Sprl Methods
JP7571008B2 (ja) * 2018-08-23 2024-10-22 アイガー・バイオファーマシューティカルズ・インコーポレイテッド インターフェロンラムダでのデルタ肝炎ウイルス感染処置
EP3999101A1 (en) 2019-07-18 2022-05-25 ENYO Pharma Method for decreasing adverse-effects of interferon
WO2021034101A1 (ko) * 2019-08-21 2021-02-25 한국과학기술원 신규 인터페론 람다 변이체 및 이의 제조방법
EP4100047A4 (en) * 2020-02-06 2024-03-13 Eiger Biopharmaceuticals, Inc. TREATMENT OF CORONAVIRUS INFECTION WITH INTERFERON LAMBDA

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007531741A (ja) * 2004-04-02 2007-11-08 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２８およびｉｌ−２９システイン変異体を用いるウイルス感染を治療するための方法
JP2014525939A (ja) * 2011-08-25 2014-10-02 ナノジェン・ファーマシューティカル・バイオテクノロジー ペグインターフェロンλ１複合体
JP2015528449A (ja) * 2012-08-30 2015-09-28 レプリコール インコーポレーティッド Ｂ型肝炎感染及びｄ型肝炎感染の治療方法
WO2015168648A1 (en) * 2014-05-01 2015-11-05 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60135393D1 (de) 2000-06-30 2008-09-25 Zymogenetics Inc Allelische Variante des Interferon-ähnlichen Proteins Zcyto21
US7038032B2 (en) 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
CA2503305A1 (en) 2002-10-23 2004-05-06 Zymogenetics, Inc. Methods for treating viral infection using il-28 and il-29
CA2520148A1 (en) 2003-04-01 2004-12-23 Intermune, Inc. Compositions and methods for treating coronavirus infection and sars
EP2251352A1 (en) 2003-08-07 2010-11-17 ZymoGenetics, L.L.C. Homogeneous preparations of IL-28 and IL-29
WO2006076014A2 (en) 2004-04-30 2006-07-20 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Interferon-alpha constructs for use in the treatment of sars
AU2006272937A1 (en) 2005-07-20 2007-02-01 Bristol-Myers Squibb Company Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders
EP1912668A2 (en) 2005-07-20 2008-04-23 ZymoGenetics, Inc. Il28 and il29 truncated cysteine mutants and antiviral methods of using same
CA2625208A1 (en) 2005-10-04 2007-04-12 Zymogenetics, Inc. Production and purification of il-29
CN102886052B (zh) * 2006-09-14 2014-07-30 迈德詹尼克斯医疗以色列有限公司 长效药物制剂
KR101652767B1 (ko) 2008-04-04 2016-08-31 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｉｌ-28을 이용한 백신 및 면역치료제, 및 그를 사용하는 방법 및 조성물
WO2011088126A2 (en) 2010-01-13 2011-07-21 Eiger Biopharmaceuticals, Inc. Treatment of viral infection with prenyltransferase inhibitors
AU2012237295A1 (en) 2011-04-01 2013-09-19 Novartis Ag Treatment for infection with Hepatitis B virus alone or in combination with Hepatitis Delta virus and associated liver diseases
CN103732250A (zh) * 2011-06-14 2014-04-16 全球免疫股份有限公司 基于酵母的治疗或预防丁型肝炎病毒感染的组合物和方法
US8454947B1 (en) 2012-03-01 2013-06-04 Nanogen Pharmaceutical Biotechnology PEG-interferon lambda 1 conjugates
TW201427664A (zh) 2012-11-02 2014-07-16 Pharmacyclics Inc Ｔｅｃ家族激酶抑制劑佐劑療法
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US20180338993A1 (en) 2014-12-04 2018-11-29 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016172342A1 (en) 2015-04-21 2016-10-27 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
EP3370723B1 (en) * 2015-11-04 2020-12-16 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
JP7674628B2 (ja) 2016-02-19 2025-05-12 イーアイティー・ファーマ・インコーポレイテッド インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置
GB201621728D0 (en) 2016-12-20 2017-02-01 Ucb Biopharma Sprl Methods
JP7571008B2 (ja) 2018-08-23 2024-10-22 アイガー・バイオファーマシューティカルズ・インコーポレイテッド インターフェロンラムダでのデルタ肝炎ウイルス感染処置
US20220387432A1 (en) 2019-09-19 2022-12-08 Eip Pharma, Inc. Compositions and methods for treating prion disease
EP4100047A4 (en) 2020-02-06 2024-03-13 Eiger Biopharmaceuticals, Inc. TREATMENT OF CORONAVIRUS INFECTION WITH INTERFERON LAMBDA

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007531741A (ja) * 2004-04-02 2007-11-08 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２８およびｉｌ−２９システイン変異体を用いるウイルス感染を治療するための方法
JP2014525939A (ja) * 2011-08-25 2014-10-02 ナノジェン・ファーマシューティカル・バイオテクノロジー ペグインターフェロンλ１複合体
JP2015528449A (ja) * 2012-08-30 2015-09-28 レプリコール インコーポレーティッド Ｂ型肝炎感染及びｄ型肝炎感染の治療方法
WO2015168648A1 (en) * 2014-05-01 2015-11-05 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KATJA GIERSCH等: "Pegylated Interferon Lambda efficiently suppresses HDV productivity and shows comparable ability to induce ISGs as peg-IFNα in HBV/HDV co-infected humanized mice", 《EASL MONOTHEMATIC CONFERENCE ON TRANSLATIONAL RESEARCH IN VIRAL HEPATITIS IN LYON》 *
沈志平等: "高剂干扰素治疗慢性丁型肝炎的疗效", 《国外医学.药学分册》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114555079A (zh) * 2019-10-16 2022-05-27 艾格尔峰生物制药有限公司 治疗丁型肝炎病毒感染的方法

Also Published As

Publication number Publication date
EP3416675B1 (en) 2021-03-24
KR20180110127A (ko) 2018-10-08
SMT202100335T1 (it) 2021-07-12
EP3416675A1 (en) 2018-12-26
US20210228686A1 (en) 2021-07-29
EP3416675A4 (en) 2020-01-08
HUE055343T2 (hu) 2022-05-28
US12508297B2 (en) 2025-12-30
HRP20210862T1 (hr) 2021-09-17
WO2017143253A1 (en) 2017-08-24
JP2022172279A (ja) 2022-11-15
JP7674628B2 (ja) 2025-05-12
JP2024156840A (ja) 2024-11-06
US10953072B2 (en) 2021-03-23
EP3957319A1 (en) 2022-02-23
PT3416675T (pt) 2021-06-14
RS61944B1 (sr) 2021-07-30
ES3008560T3 (en) 2025-03-24
EP3416675B9 (en) 2021-07-14
US20190111110A1 (en) 2019-04-18
SI3416675T1 (sl) 2021-09-30
ES2874592T3 (es) 2021-11-05
CY1124220T1 (el) 2022-05-27
DK3416675T3 (da) 2021-06-14
EP3957319B1 (en) 2024-12-04
JP2019505553A (ja) 2019-02-28
PL3416675T3 (pl) 2021-10-11
LT3416675T (lt) 2021-06-25

Similar Documents

Publication Publication Date Title
CN108883156A (zh) 用干扰素λ治疗丁型肝炎病毒感染
Antonelli et al. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-α2 therapy
JP7571008B2 (ja) インターフェロンラムダでのデルタ肝炎ウイルス感染処置
US20180110796A1 (en) Compositions and methods for the treatment of hbv infection
JP2014532657A (ja) Ｃ型肝炎ウイルスを処置するための方法および組成物
JP3208138B2 (ja) ウイルス性肝炎の診断及び治療
KR20220139922A (ko) 인터페론 람다로의 코로나바이러스 감염의 치료
AU2020368402A1 (en) Methods to treat hepatitis delta viral infections
JP2000506839A (ja) 天然ヒトα―インターフェロンを含む薬剤組成物
WO2022115765A1 (en) Treatment of hepatitis e virus infection with interferon lambda
JP2015509980A (ja) Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法
US20150164975A1 (en) Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: California, USA

Applicant after: EIT Pharmaceutical Co.

Address before: California, USA

Applicant before: Aigerfeng Innovative Therapy Co.

Country or region before: U.S.A.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250714

Address after: California, USA

Applicant after: Aigerfeng Innovative Therapy Co.

Country or region after: U.S.A.

Address before: California, USA

Applicant before: EIGER BIOPHARMACEUTICALS, Inc.

Country or region before: U.S.A.